Psoriasis Treatment Market By Treatment Type (Systemic Treatments {Biologics, Oral Medication [Methotrexate, Cyclosporine, Acitretin]}, Topical Treatments {Corticosteroids, Vitamin D Analogs, Retinoids, Calcineurin Inhibitors}, Phototherapy {UVB Therapy, PUVA (Psoralen + UVA), Excimer Laser}), By Disease Severity (Mild, Moderate, Severe), By Route of Administration (Topical, Oral, Injectable, Intravenous), and By Distribution Channel (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Psoriasis Treatment Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Innovative biologic therapies provide targeted and effective treatment options.

3.2.2. Increased awareness boosts patient consultations and treatment prescriptions significantly.

3.2.3. Rising prevalence of psoriasis globally increases demand for treatments.

3.3. Key industry pitfalls & challenges

3.3.1. Economic downturns reduce healthcare spending, impacting treatment market growth.

3.3.2. Competition from alternative treatments affects demand for pharmaceuticals negatively.

3.3.3. Stringent regulatory approvals delay availability of new treatments significantly.

3.4. Market Opportunities

3.4.1. Combination therapies can provide improved outcomes for patients effectively.

3.4.2. Focus on mild cases expands treatment options for more patients.

3.4.3. Development of personalized medicine improves efficacy and patient satisfaction.

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Psoriasis Treatment Market, Treatment Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Treatment Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Systemic Treatments

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.2. Biologics

4.2.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.3. Oral Medication

4.2.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.3.2. Methotrexate

4.2.3.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.3.3. Cyclosporine

4.2.3.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.3.4. Acitretin

4.2.3.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Topical Treatments

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.2. Corticosteroids

4.3.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.3. Vitamin D Analogs

4.3.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.4. Retinoids

4.3.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.5. Calcineurin Inhibitors

4.3.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Phototherapy

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4.2. UVB Therapy

4.4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4.3. PUVA (Psoralen + UVA)

4.4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4.4. Excimer Laser

4.4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Psoriasis Treatment Market, Disease Severity Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Disease Severity, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Mild

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Moderate

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Severe

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Psoriasis Treatment Market, Route of Administration Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Topical

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Oral

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Injectable

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Intravenous

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Psoriasis Treatment Market, Distribution Channel Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Distribution Channel, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Hospitals

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Specialty Clinics

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Retail Pharmacies

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Online Pharmacies

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Psoriasis Treatment Market, Region Segment Analysis

8.1. Overview

8.1.1. Global Market Revenue Share, By Region, 2025 & 2035

8.1.2. Global Market Revenue, By Region, 2025-2035(USD Billion)

8.2. North America

8.2.1. North America Market Revenue, By Country, 2025-2035(USD Billion)

8.2.2. North America Market Revenue, By Treatment Type, 2025-2035

8.2.3. North America Market Revenue, By Disease Severity, 2025-2035

8.2.4. North America Market Revenue, By Route of Administration, 2025-2035

8.2.5. North America Market Revenue, By Distribution Channel, 2025-2035

8.2.6. The U.S.

8.2.6.1. U.S. Market Revenue, By Treatment Type, 2025-2035

8.2.6.2. U.S. Market Revenue, By Disease Severity, 2025-2035

8.2.6.3. U.S. Market Revenue, By Route of Administration, 2025-2035

8.2.6.4. U.S. Market Revenue, By Distribution Channel, 2025-2035

8.2.7. Canada

8.2.7.1. Canada Market Revenue, By Treatment Type, 2025-2035

8.2.7.2. Canada Market Revenue, By Disease Severity, 2025-2035

8.2.7.3. Canada Market Revenue, By Route of Administration, 2025-2035

8.2.7.4. Canada Market Revenue, By Distribution Channel, 2025-2035

8.3. Europe

8.3.1. Europe Market Revenue, By Country, 2025-2035(USD Billion)

8.3.2. Europe Market Revenue, By Treatment Type, 2025-2035

8.3.3. Europe Market Revenue, By Disease Severity, 2025-2035

8.3.4. Europe Market Revenue, By Route of Administration, 2025-2035

8.3.5. Europe Market Revenue, By Distribution Channel, 2025-2035

8.3.6. Germany

8.3.6.1. Germany Market Revenue, By Treatment Type, 2025-2035

8.3.6.2. Germany Market Revenue, By Disease Severity, 2025-2035

8.3.6.3. Germany Market Revenue, By Route of Administration, 2025-2035

8.3.6.4. Germany Market Revenue, By Distribution Channel, 2025-2035

8.3.7. France

8.3.7.1. France Market Revenue, By Treatment Type, 2025-2035

8.3.7.2. France Market Revenue, By Disease Severity, 2025-2035

8.3.7.3. France Market Revenue, By Route of Administration, 2025-2035

8.3.7.4. France Market Revenue, By Distribution Channel, 2025-2035

8.3.8. U.K.

8.3.8.1. U.K. Market Revenue, By Treatment Type, 2025-2035

8.3.8.2. U.K. Market Revenue, By Disease Severity, 2025-2035

8.3.8.3. U.K. Market Revenue, By Route of Administration, 2025-2035

8.3.8.4. U.K. Market Revenue, By Distribution Channel, 2025-2035

8.3.9. Italy

8.3.9.1. Italy Market Revenue, By Treatment Type, 2025-2035

8.3.9.2. Italy Market Revenue, By Disease Severity, 2025-2035

8.3.9.3. Italy Market Revenue, By Route of Administration, 2025-2035

8.3.9.4. Italy Market Revenue, By Distribution Channel, 2025-2035

8.3.10. Spain

8.3.10.1. Spain Market Revenue, By Treatment Type, 2025-2035

8.3.10.2. Spain Market Revenue, By Disease Severity, 2025-2035

8.3.10.3. Spain Market Revenue, By Route of Administration, 2025-2035

8.3.10.4. Spain Market Revenue, By Distribution Channel, 2025-2035

8.3.11. Rest of Europe

8.3.11.1. Rest of Europe Market Revenue, By Treatment Type, 2025-2035

8.3.11.2. Rest of Europe Market Revenue, By Disease Severity, 2025-2035

8.3.11.3. Rest of Europe Market Revenue, By Route of Administration, 2025-2035

8.3.11.4. Rest of Europe Market Revenue, By Distribution Channel, 2025-2035

8.4. Asia Pacific

8.4.1. Asia Pacific Market Revenue, By Country, 2025-2035(USD Billion)

8.4.2. Asia Pacific Market Revenue, By Treatment Type, 2025-2035

8.4.3. Asia Pacific Market Revenue, By Disease Severity, 2025-2035

8.4.4. Asia Pacific Market Revenue, By Route of Administration, 2025-2035

8.4.5. Asia Pacific Market Revenue, By Distribution Channel, 2025-2035

8.4.6. China

8.4.6.1. China Market Revenue, By Treatment Type, 2025-2035

8.4.6.2. China Market Revenue, By Disease Severity, 2025-2035

8.4.6.3. China Market Revenue, By Route of Administration, 2025-2035

8.4.6.4. China Market Revenue, By Distribution Channel, 2025-2035

8.4.7. Japan

8.4.7.1. Japan Market Revenue, By Treatment Type, 2025-2035

8.4.7.2. Japan Market Revenue, By Disease Severity, 2025-2035

8.4.7.3. Japan Market Revenue, By Route of Administration, 2025-2035

8.4.7.4. Japan Market Revenue, By Distribution Channel, 2025-2035

8.4.8. India

8.4.8.1. India Market Revenue, By Treatment Type, 2025-2035

8.4.8.2. India Market Revenue, By Disease Severity, 2025-2035

8.4.8.3. India Market Revenue, By Route of Administration, 2025-2035

8.4.8.4. India Market Revenue, By Distribution Channel, 2025-2035

8.4.9. Australia

8.4.9.1. Australia Market Revenue, By Treatment Type, 2025-2035

8.4.9.2. Australia Market Revenue, By Disease Severity, 2025-2035

8.4.9.3. Australia Market Revenue, By Route of Administration, 2025-2035

8.4.9.4. Australia Market Revenue, By Distribution Channel, 2025-2035

8.4.10. South Korea

8.4.10.1. South Korea Market Revenue, By Treatment Type, 2025-2035

8.4.10.2. South Korea Market Revenue, By Disease Severity, 2025-2035

8.4.10.3. South Korea Market Revenue, By Route of Administration, 2025-2035

8.4.10.4. South Korea Market Revenue, By Distribution Channel, 2025-2035

8.4.11. Singapore

8.4.11.1. Singapore Market Revenue, By Treatment Type, 2025-2035

8.4.11.2. Singapore Market Revenue, By Disease Severity, 2025-2035

8.4.11.3. Singapore Market Revenue, By Route of Administration, 2025-2035

8.4.11.4. Singapore Market Revenue, By Distribution Channel, 2025-2035

8.4.12. Rest of Asia Pacific

8.4.12.1. Rest of Asia Pacific Market Revenue, By Treatment Type, 2025-2035

8.4.12.2. Rest of Asia Pacific Market Revenue, By Disease Severity, 2025-2035

8.4.12.3. Rest of Asia Pacific Market Revenue, By Route of Administration, 2025-2035

8.4.12.4. Rest of Asia Pacific Market Revenue, By Distribution Channel, 2025-2035

8.5. Latin America

8.5.1. Latin America Market Revenue, By Country, 2025-2035(USD Billion)

8.5.2. Latin America Market Revenue, By Treatment Type, 2025-2035

8.5.3. Latin America Market Revenue, By Disease Severity, 2025-2035

8.5.4. Latin America Market Revenue, By Route of Administration, 2025-2035

8.5.5. Latin America Market Revenue, By Distribution Channel, 2025-2035

8.5.6. Brazil

8.5.6.1. Brazil Market Revenue, By Treatment Type, 2025-2035

8.5.6.2. Brazil Market Revenue, By Disease Severity, 2025-2035

8.5.6.3. Brazil Market Revenue, By Route of Administration, 2025-2035

8.5.6.4. Brazil Market Revenue, By Distribution Channel, 2025-2035

8.5.7. Argentina

8.5.7.1. Argentina Market Revenue, By Treatment Type, 2025-2035

8.5.7.2. Argentina Market Revenue, By Disease Severity, 2025-2035

8.5.7.3. Argentina Market Revenue, By Route of Administration, 2025-2035

8.5.7.4. Argentina Market Revenue, By Distribution Channel, 2025-2035

8.5.8. Mexico

8.5.8.1. Mexico Market Revenue, By Treatment Type, 2025-2035

8.5.8.2. Mexico Market Revenue, By Disease Severity, 2025-2035

8.5.8.3. Mexico Market Revenue, By Route of Administration, 2025-2035

8.5.8.4. Mexico Market Revenue, By Distribution Channel, 2025-2035

8.5.9. Rest of Latin America

8.5.9.1. Rest of Latin America Market Revenue, By Treatment Type, 2025-2035

8.5.9.2. Rest of Latin America Market Revenue, By Disease Severity, 2025-2035

8.5.9.3. Rest of Latin America Market Revenue, By Route of Administration, 2025-2035

8.5.9.4. Rest of Latin America Market Revenue, By Distribution Channel, 2025-2035

8.6. MEA

8.6.1. MEA Market Revenue, By Country, 2025-2035(USD Billion)

8.6.2. MEA Market Revenue, By Treatment Type, 2025-2035

8.6.3. MEA Market Revenue, By Disease Severity, 2025-2035

8.6.4. MEA Market Revenue, By Route of Administration, 2025-2035

8.6.5. MEA Market Revenue, By Distribution Channel, 2025-2035

8.6.6. GCC Countries

8.6.6.1. GCC Countries Market Revenue, By Treatment Type, 2025-2035

8.6.6.2. GCC Countries Market Revenue, By Disease Severity, 2025-2035

8.6.6.3. GCC Countries Market Revenue, By Route of Administration, 2025-2035

8.6.6.4. GCC Countries Market Revenue, By Distribution Channel, 2025-2035

8.6.7. South Africa

8.6.7.1. South Africa Market Revenue, By Treatment Type, 2025-2035

8.6.7.2. South Africa Market Revenue, By Disease Severity, 2025-2035

8.6.7.3. South Africa Market Revenue, By Route of Administration, 2025-2035

8.6.7.4. South Africa Market Revenue, By Distribution Channel, 2025-2035

8.6.8. Rest of Middle-East & Africa

8.6.8.1. Rest of Middle-East & Africa Market Revenue, By Treatment Type, 2025-2035

8.6.8.2. Rest of Middle-East & Africa Market Revenue, By Disease Severity, 2025-2035

8.6.8.3. Rest of Middle-East & Africa Market Revenue, By Route of Administration, 2025-2035

8.6.8.4. Rest of Middle-East & Africa Market Revenue, By Distribution Channel, 2025-2035

9. Company Profile

9.1. AbbVie

9.1.1. Business Overview

9.1.2. Financial Performance

9.1.3. Product/Service Offerings

9.1.4. Strategies & recent developments

9.1.5. SWOT Analysis

9.2. Amgen

9.2.1. Business Overview

9.2.2. Financial Performance

9.2.3. Product/Service Offerings

9.2.4. Strategies & recent developments

9.2.5. SWOT Analysis

9.3. Johnson & Johnson

9.3.1. Business Overview

9.3.2. Financial Performance

9.3.3. Product/Service Offerings

9.3.4. Strategies & recent developments

9.3.5. SWOT Analysis

9.4. Novartis

9.4.1. Business Overview

9.4.2. Financial Performance

9.4.3. Product/Service Offerings

9.4.4. Strategies & recent developments

9.4.5. SWOT Analysis

9.5. Pfizer

9.5.1. Business Overview

9.5.2. Financial Performance

9.5.3. Product/Service Offerings

9.5.4. Strategies & recent developments

9.5.5. SWOT Analysis

9.6. Bristol-Myers Squibb

9.6.1. Business Overview

9.6.2. Financial Performance

9.6.3. Product/Service Offerings

9.6.4. Strategies & recent developments

9.6.5. SWOT Analysis

9.7. Eli Lilly

9.7.1. Business Overview

9.7.2. Financial Performance

9.7.3. Product/Service Offerings

9.7.4. Strategies & recent developments

9.7.5. SWOT Analysis

9.8. GSK

9.8.1. Business Overview

9.8.2. Financial Performance

9.8.3. Product/Service Offerings

9.8.4. Strategies & recent developments

9.8.5. SWOT Analysis

9.9. Dermira

9.9.1. Business Overview

9.9.2. Financial Performance

9.9.3. Product/Service Offerings

9.9.4. Strategies & recent developments

9.9.5. SWOT Analysis

9.10. Incyte

9.10.1. Business Overview

9.10.2. Financial Performance

9.10.3. Product/Service Offerings

9.10.4. Strategies & recent developments

9.10.5. SWOT Analysis

9.11. Sanofi

9.11.1. Business Overview

9.11.2. Financial Performance

9.11.3. Product/Service Offerings

9.11.4. Strategies & recent developments

9.11.5. SWOT Analysis

9.12. Celgene

9.12.1. Business Overview

9.12.2. Financial Performance

9.12.3. Product/Service Offerings

9.12.4. Strategies & recent developments

9.12.5. SWOT Analysis

9.13. AstraZeneca

9.13.1. Business Overview

9.13.2. Financial Performance

9.13.3. Product/Service Offerings

9.13.4. Strategies & recent developments

9.13.5. SWOT Analysis

9.14. UCB

9.14.1. Business Overview

9.14.2. Financial Performance

9.14.3. Product/Service Offerings

9.14.4. Strategies & recent developments

9.14.5. SWOT Analysis

9.15. Mylan

9.15.1. Business Overview

9.15.2. Financial Performance

9.15.3. Product/Service Offerings

9.15.4. Strategies & recent developments

9.15.5. SWOT Analysis